Carrier advocacy coverage letter for liver directed therapy (SIRT/TARE)

The liver-directed therapies evidence-based letter was written by IR physicians that are members of SIR's Carrier Advocacy Workgroup. The letter is intended to help IRs during the authorization, appeal and denial process with any payor denying this service.

Policy coverage topic: selective internal radiation therapy (SIRT), also known as transarterial radioembolization (TARE), for the treatment of metastatic colorectal cancer to the liver.

A subscription model applies to this product. The text, graphics and information are of a general nature; it is not a substitute for obtaining medical advice. We may update the documents at any time without prior notice.